Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients [MA25.03]

Mezquita, L.; Gataa, I.; Rossoni, C.; Auclin, E.; Kossai, M.; Aboubakar Nana, Frank; Le Moulec, S.; Massé, J.; Masson, M.; Radosevic-Robin, N.; Rouanne, M.; Bluthgen, M.; Caramella, C.; Hendriks, L.; Gazzah, A.; Planchard, D.; Pignon, J.; Besse, B.; Adam, J.

doi:10.1016/j.jtho.2019.08.711

Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients [MA25.03]

Mezquita, L.

;

Gataa, I.

;

Rossoni, C.

;

Auclin, E.

;

Adam, J.

;et.al.

(2019) IASLC 2019 World Conference on Lung Cancer — Location: (Spain) Barcelona (7.September.2019)

Files

2019_Mezquita_J_Thorac_Oncol_MA2503.pdf

Open Access
Adobe PDF
639.94 KB

Download

Details

Authors

Mezquita, L.
Author
Gataa, I.
Author
Rossoni, C.
Author
Auclin, E.
Author
Aboubakar Nana, FrankUCLouvain
Author
Adam, J.
Author

Abstract

BACKGROUND : Tumor infiltrating lymphocytes (TIL) morphologically assessed is prognostic in early stages in several tumors. We previously reported the correlation of TIL with immune checkpoint inhibitors (ICI) outcomes in 98 advanced (a) NSCLC patients treated with ICI. We aimed to assess the role of TIL in a larger cohort treated with ICI, and in patients exclusively treated with chemotherapy (CT). [...]

Affiliations

Citations

APA
Chicago
FWB

Mezquita, L., Gataa, I., Rossoni, C., Auclin, E., Kossai, M., Aboubakar Nana, F., Le Moulec, S., Massé, J., Masson, M., Radosevic-Robin, N., Rouanne, M., Bluthgen, M., Caramella, C., Hendriks, L., Gazzah, A., Planchard, D., Pignon, J., Besse, B., & Adam, J. (2019). Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients [MA25.03]. Journal of Thoracic Oncology, 14(10), S351-S352. https://doi.org/10.1016/j.jtho.2019.08.711 (Original work published 2019)